ONTO is benefiting from rising demand and Dragonfly adoption, but faces risks from customer concentration and volatile global macroeconomic environment.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We've got lots ...
Excuse me while I bemoan this deplorable stint of indooredness being forced upon me, compliments of the Arctic. Frostbite potential notwithstanding, I will likely venture out to do some heavily ...